Sutro Biopharma Company Leadership
| STRO Stock | USD 0.80 0.02 2.93% |
Sutro Biopharma's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Sutro Biopharma suggests that virtually all insiders are panicking. Sutro Biopharma employs about 310 people. The company is managed by 17 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 18.24 employees per reported executive.
| Shabbir Anik Executive Chief Technical Operations Officer |
| Edward Albini CFO CFO Sec |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2024-01-29 | Nicki Vasquez | Disposed 12185 @ 5 | View | ||
| 2023-08-28 | Brunilda Shtylla | Disposed 15428 @ 4.71 | View | ||
| 2023-08-25 | Brunilda Shtylla | Disposed 11613 @ 4.59 | View |
Monitoring Sutro Biopharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Sutro |
Sutro Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3474) % which means that it has lost $0.3474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.3419) %, meaning that it created substantial loss on money invested by shareholders. Sutro Biopharma's management efficiency ratios could be used to measure how well Sutro Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of March 2025, Return On Tangible Assets is likely to drop to -0.62. In addition to that, Return On Capital Employed is likely to grow to -0.89. At this time, Sutro Biopharma's Non Current Assets Total are very stable compared to the past year. As of the 21st of March 2025, Other Current Assets is likely to grow to about 18.7 M, while Total Assets are likely to drop about 304.3 M.As of the 21st of March 2025, Common Stock Shares Outstanding is likely to grow to about 80.7 M, though Net Loss is likely to grow to (101.9 M).
Sutro Biopharma Workforce Comparison
Sutro Biopharma is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,872. Sutro Biopharma retains roughly 310 in number of employees claiming about 11% of equities under Health Care industry.
Sutro Biopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sutro Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sutro Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sutro Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sutro Biopharma Notable Stakeholders
A Sutro Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sutro Biopharma often face trade-offs trying to please all of them. Sutro Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sutro Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Edward Albini | CFO Sec | Profile | |
| Edward MBA | CFO Secretary | Profile | |
| Barbara Leyman | Chief Officer | Profile | |
| Shabbir Anik | Chief Technical Operations Officer | Profile | |
| William JD | CEO Director | Profile | |
| Nicki Vasquez | Chief Officer | Profile | |
| Annie MBA | VP Relations | Profile | |
| Venkatesh Srinivasan | Chief Officer | Profile | |
| Anne MD | Chief Officer | Profile | |
| Regina Cheng | Vice Controller | Profile | |
| HansPeter Gerber | Chief Officer | Profile | |
| Trevor Hallam | Chief Scientific Officer | Profile | |
| ScD Swartz | Founder | Profile | |
| MA JD | General Counsel | Profile | |
| Jane RPh | Chief Officer | Profile | |
| Linda Fitzpatrick | Chief Officer | Profile |
About Sutro Biopharma Management Performance
The success or failure of an entity such as Sutro Biopharma often depends on how effective the management is. Sutro Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sutro management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sutro management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.93) | (0.89) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (5.10) | (4.84) |
Sutro Biopharma Workforce Analysis
Traditionally, organizations such as Sutro Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sutro Biopharma within its industry.Sutro Biopharma Manpower Efficiency
Return on Sutro Biopharma Manpower
| Revenue Per Employee | 200.1K | |
| Revenue Per Executive | 3.6M | |
| Net Loss Per Employee | 733.7K | |
| Net Loss Per Executive | 13.4M | |
| Working Capital Per Employee | 682K | |
| Working Capital Per Executive | 12.4M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth (0.87) | Return On Assets | Return On Equity |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.